Zydus launches REVAHALE, India's first once-daily nebulised LAMA for COPD

Zydus Lifesciences has launched REVAHALE (Revefenacin) in India, the country's first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) for maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). The therapy offers sustained 24-hour bronchodilation via nebulised delivery, aimed at elderly patients and those with severe respiratory issues who struggle with handheld inhalers. Clinical studies showed significant lung function improvements in moderate to very severe COPD patients with a favourable safety profile.